Trials / Available
AvailableNCT06915766
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Intermediate-Size Patient Population Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Cogent Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bezuclastinib | Drug: Bezuclastinib Tablets |
Timeline
- First posted
- 2025-04-08
- Last updated
- 2026-03-09
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06915766. Inclusion in this directory is not an endorsement.